198 related articles for article (PubMed ID: 16611189)
1. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders.
Chainuvati S; Khalid SK; Kancir S; Shea M; Edwards J; Sernyak M; Wongcharatrawee S; Garcia-Tsao G
J Viral Hepat; 2006 Apr; 13(4):235-41. PubMed ID: 16611189
[TBL] [Abstract][Full Text] [Related]
2. Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders.
Huckans MS; Loftis JM; Blackwell AD; Linke A; Hauser P
Subst Abuse Treat Prev Policy; 2007 Jan; 2():4. PubMed ID: 17222348
[TBL] [Abstract][Full Text] [Related]
3. Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans.
Dollarhide AW; Loh C; Leckband SG; Endow-Eyer R; Robinson S; Meyer JM
J Clin Gastroenterol; 2007 Mar; 41(3):322-8. PubMed ID: 17426475
[TBL] [Abstract][Full Text] [Related]
4. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
Shire NJ; Horn PS; Rouster SD; Stanford S; Eyster ME; Sherman KE;
Hepatology; 2006 Nov; 44(5):1146-57. PubMed ID: 17058240
[TBL] [Abstract][Full Text] [Related]
5. Assessment of specific antibodies to F protein in serum samples from Chinese hepatitis C patients treated with interferon plus ribavarin.
Gao DY; Zhang XX; Hou G; Jin GD; Deng Q; Kong XF; Zhang DH; Ling Y; Yu DM; Gong QM; Zhan Q; Yao BL; Lu ZM
J Clin Microbiol; 2008 Nov; 46(11):3746-51. PubMed ID: 18832124
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for hepatitis C fibrosis: a prospective study of United States veterans compared with nonveterans.
Kayali Z; Tan S; Shinkunas L; Voigt M; LaBrecque DR; Stapleton JT; Brown KE; Schmidt WN
J Viral Hepat; 2007 Jan; 14(1):11-21. PubMed ID: 17212639
[TBL] [Abstract][Full Text] [Related]
7. Identified cases of acute hepatitis C from computerized laboratory database: a hospital-based epidemiological and clinical study.
Hung CH; Lu SN; Wang JH; Hung SF; Chen CH; Hu TH; Lee CM; Changchien CS
J Infect; 2008 Apr; 56(4):274-80. PubMed ID: 18346790
[TBL] [Abstract][Full Text] [Related]
8. Utility of a depression score to predict candidacy for hepatitis C virus therapy in veterans: a prospective longitudinal study.
Tavakoli-Tabasi S; Rowan P; Abdul-Latif M; Kunik ME; El-Serag HB
Aliment Pharmacol Ther; 2005 Feb; 21(3):235-42. PubMed ID: 15691297
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life.
Cacoub P; Rosenthal E; Halfon P; Sene D; Perronne C; Pol S
J Viral Hepat; 2006 Oct; 13(10):678-82. PubMed ID: 16970599
[TBL] [Abstract][Full Text] [Related]
10. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection.
Bini EJ; Bräu N; Currie S; Shen H; Anand BS; Hu KQ; Jeffers L; Ho SB; Johnson D; Schmidt WN; King P; Cheung R; Morgan TR; Awad J; Pedrosa M; Chang KM; Aytaman A; Simon F; Hagedorn C; Moseley R; Ahmad J; Mendenhall C; Waters B; Strader D; Sasaki AW; Rossi S; Wright TL
Am J Gastroenterol; 2005 Aug; 100(8):1772-9. PubMed ID: 16086714
[TBL] [Abstract][Full Text] [Related]
11. Limited success of HCV antiviral therapy in United States veterans.
Cawthorne CH; Rudat KR; Burton MS; Brown KE; Luxon BA; Janney CG; Fimmel CJ
Am J Gastroenterol; 2002 Jan; 97(1):149-55. PubMed ID: 11808940
[TBL] [Abstract][Full Text] [Related]
12. Outcome of screening for hepatitis C virus infection based on risk factors.
Mallette C; Flynn MA; Promrat K
Am J Gastroenterol; 2008 Jan; 103(1):131-7. PubMed ID: 17894850
[TBL] [Abstract][Full Text] [Related]
13. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
[TBL] [Abstract][Full Text] [Related]
14. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.
Sharma P; Marrero JA; Fontana RJ; Greenson JK; Conjeevaram H; Su GL; Askari F; Sullivan P; Lok AS
Liver Transpl; 2007 Aug; 13(8):1100-8. PubMed ID: 17377914
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of disease in U.S. veteran patients with hepatitis C.
Nguyen HA; Miller AI; Dieperink E; Willenbring ML; Tetrick LL; Durfee JM; Ewing SL; Ho SB
Am J Gastroenterol; 2002 Jul; 97(7):1813-20. PubMed ID: 12135041
[TBL] [Abstract][Full Text] [Related]
16. Sustained virologic response to treatment in 100% of patients recently infected, nosocomially, with HCV genotype 2.
Sikuler E; Tur-Kaspa R; Shemer-Avni Y; Delgado J; Zilberman D; Fich A; Baruch Y; Hyam E
J Clin Gastroenterol; 2008 Jul; 42(6):730-3. PubMed ID: 18574394
[TBL] [Abstract][Full Text] [Related]
17. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans.
Butt AA; Khan UA; McGinnis KA; Skanderson M; Kent Kwoh C
J Viral Hepat; 2007 Dec; 14(12):890-6. PubMed ID: 18070293
[TBL] [Abstract][Full Text] [Related]
18. Viral RNA testing in hepatitis C antibody-positive veterans.
Rongey CA; Kanwal F; Hoang T; Gifford AL; Asch SM
Am J Prev Med; 2009 Mar; 36(3):235-8. PubMed ID: 19162434
[TBL] [Abstract][Full Text] [Related]
19. [Hepatitis C virus screening in drug users in an addiction out-patient unit].
Grando-Lemaire V; Goisset P; Sorge F; Trinchet JC; Castera L; Roulot D; Sitruk V; Beaugrand M
Gastroenterol Clin Biol; 2002 Dec; 26(12):1091-6. PubMed ID: 12520196
[TBL] [Abstract][Full Text] [Related]
20. Comparison of characteristics of treated and non-treated patients with Hepatitis C infection.
Hare CB; Morris JA; Chu A; Gotz V; Loveland JJ; Hodes D; Klaskala W
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):71-6. PubMed ID: 16136612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
